| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/17/2001 | CA2390557A1 Solid preparations for oral use |
| 05/17/2001 | CA2390524A1 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity |
| 05/17/2001 | CA2390496A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2390276A1 Novel compounds to treat diabetes and associated conditions |
| 05/17/2001 | CA2390128A1 Pharmaceutical formulation |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2388729A1 Imidazopyridine derivatives as phosphodiesterase vii inhibitors |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2361139A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| 05/16/2001 | EP1099701A1 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B |
| 05/16/2001 | EP1099443A1 Transplant/implant device and method for its production |
| 05/16/2001 | EP1099442A2 Methods of administering apo B-secretion/MTP inhibitors |
| 05/16/2001 | EP1099441A2 Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof |
| 05/16/2001 | EP1099439A2 Use of apo B secretion/MTP inhibitors |
| 05/16/2001 | EP1099438A2 Use of APO B secretion/MTP inhibitors |
| 05/16/2001 | EP1098985A1 Genes of the dead box protein family, their expression products and use |
| 05/16/2001 | EP1098962A2 Diacylglycerol acyl transferase proteins |
| 05/16/2001 | EP1098906A1 Peptide analogues of pacap |
| 05/16/2001 | EP1098893A1 Cyclic compounds useful in the treatment of dyslipidemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process |
| 05/16/2001 | EP1098891A1 Polycyclic thiazolidin-2-ylidene amines, method for the production and use thereof as medicaments |
| 05/16/2001 | EP1098663A1 Slow release formulations comprising anionic polysaccharide |
| 05/16/2001 | EP1098657A1 Composition for treating obesity and aesthetic treatment method |
| 05/16/2001 | EP1098655A2 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 05/16/2001 | EP1098654A1 Antilipemic composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098640A1 Anti-ulcer composition comprising a polysaccharide containing glucuronic acid |
| 05/16/2001 | EP1098639A1 Use of a glucose uptake enhancer for reducing apoptosis |
| 05/16/2001 | EP1011673B1 Novel niddm regimen |
| 05/16/2001 | EP0982990A4 Stable liquid mineral ascorbate compositions and methods of manufacture and use |
| 05/16/2001 | EP0842165B1 Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 05/16/2001 | CN1295467A Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 05/16/2001 | CN1295064A Novel tricyclic compound and medicine composition containing the same |
| 05/16/2001 | CN1295060A Intermediate for preparing allyl quinone derivative and prep. of the same |
| 05/16/2001 | CN1294912A Blood sugar reducing compound |
| 05/16/2001 | CN1065863C N-substituted dioxothiazolidylbenzamide derivatives and process for producing same |
| 05/16/2001 | CN1065861C Phenyl substituted alkenocarboxylic guanidine, preparation method application as medicine or diagnostic agent and medicine containing it |
| 05/16/2001 | CN1065762C Medical capsule for regulating insulin and reducing blood and/or uric sugar |
| 05/16/2001 | CN1065753C Hypoylycemic instant powder and prepn. thereof |
| 05/15/2001 | US6232351 Which comprises a botanical plant, microcrystalline cellulose and calcium carbonate co-processed in an aqueous slurry then spray dried; vitamins and food supplements; good disintegration, compressibility |
| 05/15/2001 | US6232345 Cerebral function improving agents |
| 05/15/2001 | US6232337 Useful in the treatment of type ii diabetes and obesity |
| 05/15/2001 | US6232330 Therapeutically effective amount of an insulin sensitivity enhancer(pioglitazone,troglitazone and salts) in combination with an aldose reductase inhibitor(tolurestat,epalrestat,imirestat,zenarestat) |
| 05/15/2001 | US6232313 Pyridazino quinoline compounds |
| 05/15/2001 | US6232307 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole compounds useful as estrogenic agents |
| 05/15/2001 | US6231882 Mixed micellar delivery system and method of preparation |
| 05/15/2001 | CA2034612C Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase |
| 05/15/2001 | CA2009669C Novel n-¬substituted aryl|-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001032923A1 Antisense inhibition of pi3 kinase p55 gamma expression |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032878A2 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032837A1 19 human secreted proteins |
| 05/10/2001 | WO2001032830A2 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 05/10/2001 | WO2001032714A1 Recombinant fusion molecules |
| 05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
| 05/10/2001 | WO2001032705A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | WO2001032695A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032670A1 Oxetanone derivatives |
| 05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032638A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032625A1 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032624A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032616A2 Oxetanone derivatives |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032608A1 Process for the preparation of oxyiminoalkanoic acid derivatives |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032601A1 Polymorphic forms of sertraline hydrochloride |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032222A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | WO2001032220A1 Gene therapy for diabetic ischemic disease |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032200A1 Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
| 05/10/2001 | WO2001032195A1 Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (trh) |
| 05/10/2001 | WO2001032192A1 Active substance in ganoderma lucidum extract and drugs, health foods and cosmetics containing the same |
| 05/10/2001 | WO2001032186A2 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 05/10/2001 | WO2001032162A1 Liver selective therapy |
| 05/10/2001 | WO2001032160A2 Modification of cholesterol concentrations with citrus phytochemicals |
| 05/10/2001 | WO2001032158A2 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent |
| 05/10/2001 | WO2001032157A2 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032137A1 Slimming composition containing a substance inducing il-6 production |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |